Adamed amongst 10 Most Innovative Pharmaceutical Companies 2016

Gazeta Finansowa conducted an analysis of the most innovative solutions among companies from the pharmaceutical sector in Poland. Adamed Group, with its flagship project ONCO-3CLA, was awarded a place among the 10 Most Innovative Pharmaceutical Companies of 2016.

The aim of ONCO-3CLA is to develop a novel biotechnological molecule which neutralises neoplastic cells while not damaging healthy cells in the patient’s body. The programme was created through a proprietary technology platform for the development of a special carrier – a guidance system for cells. ONCO-3CLA is co-financed by the European Union, from the European Regional Development Fund.

ONCOTRAIL, a continuation of the ONCO-3CLA project, is aimed at conducting phase 1 clinical trials of the targeted biotechnological molecule developed by Adamed Group’s R&D Department and at establishing Poland’s first clinical trial centre for conducting early phase oncological trials. The project is implemented by a consortium including the Maria Skłodowska-Curie Institute of Oncology, Adamed Group, Institute of Haematology and Transfusion Medicine, Medical Centre for Postgraduate Education and Institute of Mother and Child. It is co-financed under the STRATEGMED programme.